Viral Infection of HSPC Impacts Hematopoiesis
MEGAHOST
Virus-induced Immunosuppression Via Infection of Hematopoietic Progenitors
2 other identifiers
observational
45
1 country
1
Brief Summary
We propose to demonstrate that HIV-1 and SARS-CoV-2 are capable of targeting long-lived HSPC with self-renewal capacities. These progenitors, thus transformed into host cells, can give rise to a durable source of infected cells with an impact on hematopoiesis.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Oct 2024
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 10, 2024
CompletedFirst Posted
Study publicly available on registry
June 13, 2024
CompletedStudy Start
First participant enrolled
October 25, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
March 1, 2026
CompletedMarch 20, 2025
March 1, 2025
1.3 years
June 10, 2024
March 17, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Evaluate if infected HSPC would modulate the bone marrow environment
Evaluate whether these infected HSPC would modulate the bone marrow environment by upregulating inflammatory cytokines detrimental to lymphopoiesis.
at 1 year
Eligibility Criteria
* adult patients. * patients able to read and understand the information note. * no opposition to the use of biological samples. 45 subjects are required in our study: (A) 20 patients with FFPE osteomedullary biopsy prior to COVID-19 pandemic. Including : * 10 HIVpos patients selected based on biopsy results (normal, subnormal/minor lesion). * 10 HIVneg patients selected to match HIVpos patients, considering age and biological sex. (B) 25 HIVneg patients asymptomatic for COVID-19 for whom a myelogram or BM biopsy is prescribed as part of a search for haematological pathology or as part of lymphoma extension investigations.
You may qualify if:
- HIV patients :
- HIV-positive patients with a negative or positive viral load.
- managed at Ambroise Paré Hospital.
- patients with a bone marrow biopsy or myelogram performed as part of their care.
- Healthy subjects without HIV - patients with a BM biopsy or myelogram performed as part of their care for a suspected hematological pathology.
- Management at Ambroise Paré Hospital.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Hematology and interne medicine department, Ambroise Paré hospital - APHP
Boulogne-Billancourt, 92100, France
Study Officials
- PRINCIPAL INVESTIGATOR
Claude CAPRON, MD, PhD
Laboratory of Immunology, Ambroise Paré hospital - APHP
- STUDY DIRECTOR
Fernando REAL, PhD
Center for Infection and Immunity of Lille, INSERM U1019 - CNRS UMR9017, Institut Pasteur de Lille
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 10, 2024
First Posted
June 13, 2024
Study Start
October 25, 2024
Primary Completion
March 1, 2026
Study Completion
March 1, 2026
Last Updated
March 20, 2025
Record last verified: 2025-03